Advertisement
Screener

Aligos Therapeutics, Inc. (ALGS) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

1.5 / 5 stars · 13/43 Roast Me

Aligos Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

Aligos Therapeutics, Inc. (ALGS) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06

  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.00K.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$30.00K.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $13.00K.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $35.00K, a 57.83% decline year-over-year.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $17.00K.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$94.00K, a 165.28% decline from fiscal 2023.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $144.00K.
  • Aligos Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$51.00K, a 107.97% decline from fiscal 2021.
Period endOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month
2026-06-30-$1.00K
10-Q · filed 2026-08-06
-$31.00K
10-Q · filed 2026-08-06
-$18.00K
derived: sum of 3 quarters · filed 2026-08-06
$17.00K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$30.00K
10-Q · filed 2026-08-06
-$17.00K
derived: sum of 2 quarters · filed 2026-08-06
$18.00K
derived: sum of 3 quarters · filed 2026-08-06
-$9.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$13.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$48.00K
derived: sum of 2 quarters · filed 2026-03-05
$21.00K
derived: sum of 3 quarters · filed 2026-08-06
$17.00K
10-K · filed 2026-03-05
2025-09-30$35.00K
10-Q · filed 2025-11-06
$8.00K
derived: sum of 2 quarters · filed 2026-08-06
$4.00K
10-Q · filed 2025-11-06
-$122.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$27.00K
10-Q · filed 2026-08-06
-$31.00K
10-Q · filed 2026-08-06
-$157.00K
derived: sum of 3 quarters · filed 2026-08-06
-$74.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$4.00K
10-Q · filed 2026-08-06
-$130.00K
derived: sum of 2 quarters · filed 2026-08-06
-$47.00K
derived: sum of 3 quarters · filed 2026-08-06
-$29.00K
derived: sum of 4 quarters · filed 2026-08-06
2024-12-31-$126.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$43.00K
derived: sum of 2 quarters · filed 2026-03-05
-$25.00K
derived: sum of 3 quarters · filed 2026-03-05
-$94.00K
10-K · filed 2026-03-05
2024-09-30$83.00K
10-Q · filed 2025-11-06
$101.00K
derived: sum of 2 quarters · filed 2025-11-06
$32.00K
10-Q · filed 2025-11-06
$80.00K
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$18.00K
10-Q · filed 2025-11-06
-$51.00K
10-Q · filed 2025-08-06
-$3.00K
derived: sum of 3 quarters · filed 2025-11-06
-$3.00K
derived: sum of 4 quarters · filed 2025-11-06
2024-03-31-$69.00K
10-Q · filed 2025-11-06
-$21.00K
derived: sum of 2 quarters · filed 2025-11-06
-$21.00K
derived: sum of 3 quarters · filed 2025-11-06
-$23.00K
derived: sum of 4 quarters · filed 2025-11-06
2023-12-31$48.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10
$48.00K
derived: sum of 2 quarters · filed 2025-03-10
$46.00K
derived: sum of 3 quarters · filed 2025-03-10
$144.00K
10-K · filed 2025-03-10
2023-09-30$0.00
10-Q · filed 2023-11-02
-$2.00K
derived: sum of 2 quarters · filed 2024-08-06
$96.00K
10-Q · filed 2024-11-06
$338.00K
derived: sum of 4 quarters · filed 2024-08-06
2023-06-30-$2.00K
10-Q · filed 2024-08-06
$96.00K
10-Q · filed 2024-08-06
$338.00K
derived: sum of 3 quarters · filed 2024-08-06
$447.00K
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$98.00K
10-Q · filed 2024-05-07
$340.00K
derived: sum of 2 quarters · filed 2024-05-07
$449.00K
derived: sum of 3 quarters · filed 2024-05-07
$295.00K
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31$242.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
$351.00K
derived: sum of 2 quarters · filed 2024-03-12
$197.00K
derived: sum of 3 quarters · filed 2024-03-12
-$51.00K
10-K · filed 2024-03-12
2022-09-30$109.00K
10-Q · filed 2023-11-02
-$45.00K
derived: sum of 2 quarters · filed 2023-11-02
-$293.00K
10-Q · filed 2023-11-02
$409.00K
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30-$154.00K
10-Q · filed 2023-08-03
-$402.00K
10-Q · filed 2023-08-03
$300.00K
derived: sum of 3 quarters · filed 2023-08-03
$301.00K
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$248.00K
10-Q · filed 2023-05-04
$454.00K
derived: sum of 2 quarters · filed 2023-05-04
$455.00K
derived: sum of 3 quarters · filed 2023-05-04
$431.00K
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$702.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
$703.00K
derived: sum of 2 quarters · filed 2023-03-09
$679.00K
derived: sum of 3 quarters · filed 2023-03-09
$640.00K
10-K · filed 2023-03-09
2021-09-30$1.00K
10-Q · filed 2022-11-02
-$23.00K
derived: sum of 2 quarters · filed 2022-11-02
-$62.00K
10-Q · filed 2022-11-02
-$282.00K
derived: sum of 4 quarters · filed 2022-11-02
2021-06-30-$24.00K
10-Q · filed 2022-08-04
-$63.00K
10-Q · filed 2022-08-04
-$283.00K
derived: sum of 3 quarters · filed 2022-08-04
-$401.00K
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$39.00K
10-Q · filed 2022-05-04
-$259.00K
derived: sum of 2 quarters · filed 2022-05-04
-$377.00K
derived: sum of 3 quarters · filed 2022-05-04
-$679.00K
derived: sum of 4 quarters · filed 2022-05-04
2020-12-31-$220.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$338.00K
derived: sum of 2 quarters · filed 2022-03-10
-$640.00K
derived: sum of 3 quarters · filed 2022-03-10
-$73.00K
10-K · filed 2022-03-10
2020-09-30-$118.00K
10-Q · filed 2021-11-04
-$420.00K
derived: sum of 2 quarters · filed 2021-11-04
$147.00K
10-Q · filed 2021-11-04
$114.00K
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$302.00K
10-Q · filed 2021-08-05
$265.00K
10-Q · filed 2021-08-05
$232.00K
derived: sum of 3 quarters · filed 2021-08-05
$194.00K
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$567.00K
10-Q · filed 2021-05-10
$534.00K
derived: sum of 2 quarters · filed 2021-05-10
$496.00K
derived: sum of 3 quarters · filed 2021-05-10
2019-12-31-$33.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23
-$71.00K
derived: sum of 2 quarters · filed 2021-03-23
-$118.00K
10-K · filed 2021-03-23
2019-09-30-$38.00K
10-Q · filed 2020-11-25
-$85.00K
10-Q · filed 2020-11-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22